Purevax Rcp 1 dose of 1 mL or 0.5 mL contains Attenuated feline rhinotracheitis herpesvirus(FHV F2 strain)≥104.9 CCID50; Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens≥ 2.0 ELISA U.; Attenuated feline panleucopenia virus (PLI IV) ≥103.5 CCID50 Suspension For Injection (Sc) Philippines - English - FDA (Food And Drug Administration)

purevax rcp 1 dose of 1 ml or 0.5 ml contains attenuated feline rhinotracheitis herpesvirus(fhv f2 strain)≥104.9 ccid50; inactivated feline calicivirus (fcv 431 and fcv g1 strains) antigens≥ 2.0 elisa u.; attenuated feline panleucopenia virus (pli iv) ≥103.5 ccid50 suspension for injection (sc)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), panleucopenia virus (pli iv) and inactivated calicivirus (fcv 431) and (fcv g1 strains) - suspension for injection (sc) - 1 dose of 1 ml or 0.5 ml contains attenuated feline rhinotracheitis herpesvirus(fhv f2 strain)≥104.9 ccid50; inactivated feline calicivirus (fcv 431 and fcv g1 strains) antigens≥ 2.0 elisa u.; attenuated feline panleucopenia virus (pli iv) ≥103.5 ccid50

Purevax RCPCh FeLV European Union - English - EMA (European Medicines Agency)

purevax rcpch felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Purevax RCPCh European Union - English - EMA (European Medicines Agency)

purevax rcpch

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs.onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components.the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Purevax RCP European Union - English - EMA (European Medicines Agency)

purevax rcp

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs.onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Purevax RCP FeLV European Union - English - EMA (European Medicines Agency)

purevax rcp felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

COMPANION F3 TRIVALENT LIVING VACCINE FOR CATS Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

companion f3 trivalent living vaccine for cats

intervet australia pty limited - feline panleucopenia; feline calicivirus; live feline herpes virus - misc. vaccines or anti sera - feline panleucopenia vaccine active 0.0 undefined; feline calicivirus vaccine-viral active 0.0 undefined; live feline herpes virus vaccine-viral active 0.0 undefined - immunotherapy - cat | cat - queen | cat - tom | kitten - feline calicivirus | feline enteritis | feline leukaemia virus | feline rhinotracheitis | calicivirus (feline) | disease caused by | enteritis (feline) | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)

FELIGEN RCP TRIVALENT LIVING VACCINE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

feligen rcp trivalent living vaccine

virbac (australia) pty ltd - feline calicivirus - live; live feline herpes virus; feline panleucopenia virus - live - parenteral liquid/solution/suspension - feline calicivirus - live vaccine-viral active 12589.254 tci50/vi; live feline herpes virus vaccine-viral active 100000.0 tci50/vi; feline panleucopenia virus - live vaccine-viral active 1000.0 tci50/vi - immunotherapy - cat | cat - queen | cat - tom | kitten - feline calicivirus | feline enteritis | feline leukaemia virus | feline rhinotracheitis | calicivirus (feline) | disease caused by | enteritis (feline) | fcv | feline herpesvirus type 1 | feline infectious enteritis | feline panleucopenia (fp) | fhv-1 | fvr | herpesvirus 1 (feline) | herpesvirus type 1 (feline) | panleucopenia (feline) | rhinotracheitis (feline)

Nobivac Tricat Trio Formulation:   Each dose contains:   Feline Calicivirus (F9 strain) .....>4.6 log10 PFU Feline Viral Rhinotracheitis Virus (G2620A strain) ................>5.2 log10 PFU Feline Panleucopenia Virus (MW-1 strain) .............>4.3 log10 TCID PFU-Plaque Forming Unit TCID-Tissue Culture Infective Dose Suspension for Injection (SC) Philippines - English - FDA (Food And Drug Administration)

nobivac tricat trio formulation: each dose contains: feline calicivirus (f9 strain) .....>4.6 log10 pfu feline viral rhinotracheitis virus (g2620a strain) ................>5.2 log10 pfu feline panleucopenia virus (mw-1 strain) .............>4.3 log10 tcid pfu-plaque forming unit tcid-tissue culture infective dose suspension for injection (sc)

msd animal health (phils.), inc.; distributor: msd animal health (phils.), inc. - live attenuated feline calicivirus (fcv) , feline viral rhinotracheitis virus (fvr) , feline panleukopenia virus (fpl) vaccine (vet.) - suspension for injection (sc) - formulation: each dose contains: feline calicivirus (f9 strain) .....>4.6 log10 pfu feline viral rhinotracheitis virus (g2620a strain) ................>5.2 log10 pfu feline panleucopenia virus (mw-1 strain) .............>4.3 log10 tcid pfu-plaque forming unit tcid-tissue culture infective dose

Leucofeligen FeLV/RCP European Union - English - EMA (European Medicines Agency)

leucofeligen felv/rcp

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - live feline panleucopenia virus / parvovirus + live feline rhinotracheitis virus + live feline calicivirus + inactivated feline leukaemia virus - cats - for active immunisation of cats from eight weeks of age against:feline calicivirosis to reduce clinical signs.feline viral rhinotracheitis to reduce clinical signs and viral excretion.feline panleucopenia to prevent leucopenia and to reduce clinical signs.feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.duration of immunity: one year after the primary vaccination for all components.